Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold?

Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.

Trying to work out what would count as evidence on Amylin analogue mechanism, before collecting any. This is the part I usually skip and it is the part that makes the rest useful.

If two explanations predict the same observation, observing it does not help. So: what observation would separate them?

I read the opening post twice before replying, because I had assumed the opposite.

On Amylin analogue mechanism I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

This is the sort of thing that ought to be settled and apparently is not.

On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.

That is a cleaner way of putting what I was circling around.

Everything in post #2 holds. The case it does not cover is the one I have.

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

It cost nothing to check and would have cost something not to.

Taking post #4 at face value and following it one step further.

What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.

That is the practical version. The rigorous version is longer and says the same thing.

Checked the Amylin analogue mechanism claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.

For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

Second this, and I would have said it less carefully.

Confirming post #9 from a second method, which matters more than confirming it from a second person.

Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.

That is the version I would defend. It is not the version I started with.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

Amylin analogue mechanism would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.